SCHEMBL31301686

SCHEMBL31301686

CC(C)CNc1ncnc2[nH]cc(-c3cccc(Cl)c3)c12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK3 Q13188 16/20 0.69
STK4 Q13043 14/20 0.69
LRRK2 Q5S007 10/20 0.69
MAP4K4 O95819 4/20 0.58
BRAF P15056 1/20 0.56
TNNI3K Q59H18 1/20 0.56
PRKD3 O94806 3/20 0.50
PRKACA P17612 3/20 0.50
CLK2 P49760 3/20 0.50
GSK3A P49840 3/20 0.50
GSK3B P49841 3/20 0.50
CDK5 Q00535 3/20 0.50
MAP4K2 Q12851 3/20 0.50
ROCK1 Q13464 3/20 0.50
DYRK1A Q13627 3/20 0.50
CLK4 Q9HAZ1 3/20 0.50
CDC7 O00311 2/20 0.50
CHUK O15111 2/20 0.50
PDPK1 O15530 2/20 0.50
DYRK3 O43781 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30295797 0.93 STK3 (0.69) STK3STK4LRRK2MAP4K4BRAF
SCHEMBL30295899 0.91 STK3 (0.70) STK3STK4LRRK2MAP4K4BRAF
SCHEMBL31301799 0.90 STK3 (0.66) STK3STK4LRRK2MAP4K4BRAF
SCHEMBL31301641 0.90 STK3 (0.72) STK3STK4LRRK2MAP4K4BRAF
SCHEMBL30295832 0.90 STK3 (0.66) STK3STK4LRRK2MAP4K4BRAF
SCHEMBL30295830 0.89 STK3 (0.70) STK3STK4LRRK2MAP4K4BRAF
SCHEMBL31301726 0.88 STK3 (0.72) STK3STK4LRRK2MAP4K4BRAF
SCHEMBL30295782 0.87 STK3 (0.65) STK3STK4LRRK2MAP4K4BRAF
SCHEMBL30295913 0.87 STK3 (0.65) STK3STK4LRRK2MAP4K4BRAF
SCHEMBL30295764 0.87 STK3 (0.62) STK3STK4LRRK2MAP4K4BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051337-A1 INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF STK3, STK4, STK36 STK3 1/4885STK4 2/4885LRRK2 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.